TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19889189

Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DDD pacing mode
Number of subjects: 15
Study: 18762597

Group type: EXPERIMENTAL
Intervention: Pictogram-based medication instruction sheets
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard medication counseling
Number of subjects: 245
Study: 16253150

Group type: EXPERIMENTAL
Intervention: Pari PEP device
Number of subjects: 8

Group type: COMPARATOR
Intervention: No PEP (low-resistance Pari filter)
Number of subjects: 8
Study: 12115793

Group type: EXPERIMENTAL
Intervention: Tumor bed radiotherapy (TBRT) using interstitial high-dose-rate brachytherapy (HDR-BT) of 7 x 4.33 Gy (n = 8) and 7 x 5.2 Gy (n = 37)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Whole breast radiotherapy (WBRT) of 50 Gy (n = 63)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tumor bed radiotherapy (TBRT) of 7 x 5.2 Gy HDR-BT (n = 46)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tumor bed radiotherapy (TBRT) of 50-Gy wide-field electron irradiation (n = 17)
Number of subjects: 45
Study: 9935117

Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with physiologic (75 mIU/mL) FSH
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with supraphysiologic (7,500 mIU/mL) FSH
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with FSH alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with hCG alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with FSH with LH
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Culture medium without FBS supplemented with physiologic FSH with LH
Number of subjects: 21

Group type: COMPARATOR
Intervention: Culture medium without FBS supplemented with both concentrations of FSH alone and hCG alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Culture medium without FBS with both concentrations of FSH alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Culture medium without FBS with hCG alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Culture medium without FBS with FSH with LH
Number of subjects: 21
Study: 8688926

Group type: EXPERIMENTAL
Intervention: Normative Treatment Planning (NTP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Client Feedback System (CFS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Experimental groups (NTP and CFS)
Number of subjects: 16
Study: 2349366

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 447034

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prostaglandin A1
Number of subjects: 13
Study: 30997657

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cavit G
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Orafil-G
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dia-Temp
Number of subjects: 60
Study: 28864322

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1421

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1421
Study: 26039212

Group type: EXPERIMENTAL
Intervention: T cell-depleted haploidentical transplantation followed by infusion of genetically modified donor T cells (TK007 study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD with unmanipulated PBSCs from haploidentical family donors (TrRaMM study)
Number of subjects: 0
Study: 22915288

Group type: EXPERIMENTAL
Intervention: LB03002 (sustained-release recombinant human GH)
Number of subjects: 136
Study: 20650652

Group type: EXPERIMENTAL
Intervention: Standard care plus cooking and exercise classes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-management questionnaire (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-management questionnaire (control group)
Number of subjects: 40
Study: 19812228

Group type: COMPARATOR
Intervention: MTX (Methotrexate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNFi+MTX (TNF inhibitors combined with Methotrexate)
Number of subjects: 0
Study: 17101908

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 26
Study: 14633531

Group type: EXPERIMENTAL
Intervention: Preoperative interscalene block with 30 mL of 0.5% levobupivacaine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Postoperative interscalene block with 30 mL of 0.5% levobupivacaine
Number of subjects: 102
Study: 10975586

Group type: EXPERIMENTAL
Intervention: TAK-044 (25, 50, or 100 mg, i.v.)
Number of subjects: 24
Study: 9394260

Group type: EXPERIMENTAL
Intervention: Therapy programs for depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depressive symptomatology
Number of subjects: 0
Study: 1300902

Group type: EXPERIMENTAL
Intervention: Cervical esophago-gastrostomy (CA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thoracic esophago-gastrostomy (TA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subtotal esophagectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 60
Study: 3158620

Group type: EXPERIMENTAL
Intervention: Topically applied 2% zinc sulfate solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31063000

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (SE)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard echocardiography
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treadmill testing
Number of subjects: 111
Study: 29852804

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided percutaneous A1 pulley release
Number of subjects: 41

Group type: COMPARATOR
Intervention: Blind percutaneous A1 pulley release
Number of subjects: 41
Study: 26293542

Group type: EXPERIMENTAL
Intervention: Resource Enhancement and Activation Program (12 weeks)
Number of subjects: 64
Study: 24302681

Group type: EXPERIMENTAL
Intervention: Pregnenolone (400 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DHEA (400 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23161039

Group type: EXPERIMENTAL
Intervention: Scheduled time administration of Ketorolac (bolus after surgical incision and then every 8 hours for 24 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous infusion of Ketorolac (2 ml/h for 24 hours)
Number of subjects: 80
Study: 20832963

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180‐mg loading dose, 90 mg twice daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clopidogrel (300‐ to 600‐mg loading dose, 75 mg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clopidogrel loading dose
Number of subjects: 69
Study: 18158761

Group type: EXPERIMENTAL
Intervention: Cysteine-rich protein (IMN1207)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Casein (control)
Number of subjects: 66
Study: 16015250

Group type: EXPERIMENTAL
Intervention: Beverage with 5 g beta-glucans from oats
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Beverage with 10 g beta-glucans from oats
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Beverages with barley beta-glucans
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 100
Study: 11796602

Group type: EXPERIMENTAL
Intervention: Intranasal NOMV vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intranasal and oropharyngeal NOMV vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group receiving extra vaccine dose
Number of subjects: 42
Study: 10643695

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with >50% improvement after 1 year
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with 20-50% improvement after 1 year
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Combined group of patients with >50% and 20-50% improvement
Number of subjects: 271

Group type: COMPARATOR
Intervention: Patients without improvement after 1 year
Number of subjects: 271

Group type: COMPARATOR
Intervention: Patients who discontinued methotrexate treatment during the first year
Number of subjects: 271
Study: 9007423

Group type: EXPERIMENTAL
Intervention: Exploration of a to-scale computer simulation of a real multi-storey building
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no exploration of the real building or computer simulation)
Number of subjects: 10
Study: 1380432

Group type: EXPERIMENTAL
Intervention: Tropisetron 10mg intravenously before and after cisplatin infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tropisetron 5mg intravenously 15 minutes before cisplatin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Metoclopramide 2 mg/kg plus lorazepam administered 15 minutes before cisplatin
Number of subjects: 54
Study: 6092288

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Antacid 60 ml/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 45
Study: 30844687

Group type: EXPERIMENTAL
Intervention: Selenomethionine (200 μg daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vitamin D (4000 IU daily)
Number of subjects: 47
Study: 28911155

Group type: EXPERIMENTAL
Intervention: Glycoprotein acetyls (GlycA)
Number of subjects: 8749

Group type: EXPERIMENTAL
Intervention: Interleukin‐1 receptor antagonist (IL‐1RA)
Number of subjects: 8749

Group type: EXPERIMENTAL
Intervention: High‐sensitivity C‐reactive protein (hs‐CRP)
Number of subjects: 8749
Study: 25443268

Group type: EXPERIMENTAL
Intervention: mp‐MRI/biopsy
Number of subjects: 1140

Group type: COMPARATOR
Intervention: TRUS-guided biopsy
Number of subjects: 1140
Study: 23326188

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid alone (66 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (49.5 mg) plus diclofenac sodium (5 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (49.5 mg) plus sodium clodronate (5 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 62
Study: 21233227

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) in children with SCI
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in healthy controls
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation of DTI indices with ISNCSCI scores in children with SCI
Number of subjects: 10
Study: 17614029

Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone (Pred)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 9
Study: 16931511

Group type: EXPERIMENTAL
Intervention: RAPSN mutations R164C and L283P
Number of subjects: 2

Group type: COMPARATOR
Intervention: Wild-type AChR subunits
Number of subjects: 2
Study: 12950862

Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous remifentanil
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both interventions (isoflurane and remifentanil)
Number of subjects: 25
Study: 11020675

Group type: EXPERIMENTAL
Intervention: Manual in-line stabilization
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Miller straight blade
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cervical collar immobilization
Number of subjects: 14

Group type: COMPARATOR
Intervention: Macintosh curved blade and Corazelli-London-McCoy hinged blade
Number of subjects: 14
Study: 9116411

Group type: EXPERIMENTAL
Intervention: Body surface trigger
Number of subjects: 12

Group type: COMPARATOR
Intervention: Airway trigger
Number of subjects: 12
Study: 8505826

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation starting on the second to fourth day of life; 2000 IU intramuscularly three times a week starting on the 10th to 14th day of life, followed by 2500 IU/d orally when enteral feedings reached 60 kcal/kg per day.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vitamin A supplementation starting on the 10th to 14th day of life; 2000 IU intramuscularly three times a week, followed by 2500 IU/d orally when enteral feedings reached 60 kcal/kg per day.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 48
Study: 3087801

Group type: EXPERIMENTAL
Intervention: Terfenadine (TRF) 60 mg b.i.d. for 7 days
Number of subjects: 141

Group type: COMPARATOR
Intervention: Mequitazine (MQZ) 5 mg b.i.d. for 7 days
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Terfenadine (TRF)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Mequitazine (MQZ)
Number of subjects: 141
Study: 2819021

Group type: EXPERIMENTAL
Intervention: Skimmed milk
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ca-enriched skimmed milk
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Watercress soup
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ca-enriched milk (1 pint daily for 4 weeks)
Number of subjects: 10
Study: 29226958

Group type: EXPERIMENTAL
Intervention: Visual masking exposure (VBE) to masked spiders
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control exposure to masked flowers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearly visible exposure to spider images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual masking exposure (VBE)
Number of subjects: 60
Study: 28911092

Group type: EXPERIMENTAL
Intervention: Concurrent ovarian function suppression (OFS) with chemotherapy using triptorelin
Number of subjects: 1872

Group type: COMPARATOR
Intervention: Sequential OFS post-chemotherapy using triptorelin
Number of subjects: 1872

Group type: EXPERIMENTAL
Intervention: Concurrent OFS with chemotherapy in women <40 years at diagnosis
Number of subjects: 1872

Group type: COMPARATOR
Intervention: Sequential OFS post-chemotherapy in women <40 years at diagnosis
Number of subjects: 1872
Study: 26258561

Group type: EXPERIMENTAL
Intervention: Monitoring parenting practice
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Limit setting of soda/snacks (SS)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Limit setting of screen media (SM)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 301
Study: 23458591

Group type: EXPERIMENTAL
Intervention: LCI699 (0.25 mg twice daily, 1 mg four times daily, and 0.5 mg/1 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20579848

Group type: EXPERIMENTAL
Intervention: High dairy (∼ 1300 mg/d of calcium from dairy products)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High calcium (∼ 1300 mg/d of calcium; ∼ 700 mg/d from diet and 600 mg/d from a supplement)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19049544

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS applied to the left and right dlPFC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation (control condition)
Number of subjects: 24
Study: 16503524

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (routine intravenous oxytocin infusion)
Number of subjects: 71
Study: 15055095

Group type: EXPERIMENTAL
Intervention: Modified Hatha yoga intervention (1 hour, twice a week for 6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment during observation period)
Number of subjects: 22
Study: 11816532

Group type: EXPERIMENTAL
Intervention: Estrogen and progestin (E + P), n = 122
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Estrogen alone (E), n = 50
Number of subjects: 172
Study: 9406364

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlorpromazine and dexamethasone
Number of subjects: 66
Study: 8481745

Group type: EXPERIMENTAL
Intervention: Coping Strategy Enhancement (CSE)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Problem Solving (PS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting period (Control)
Number of subjects: 49
Study: 3320259

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 173
Study: 31596774

Group type: EXPERIMENTAL
Intervention: Peer-centered video counseling (PEER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physician video counseling (PHYS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both PEER and PHYS
Number of subjects: 0
Study: 30177236

Group type: EXPERIMENTAL
Intervention: Brexanolone 60 μg/kg per h (BRX60)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Brexanolone 90 μg/kg per h (BRX90)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 27046747

Group type: EXPERIMENTAL
Intervention: 3-D laparoscopy (Group B, n = 42)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-D laparoscopy (Group A, n = 48)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3-D laparoscopy (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-D laparoscopy (Group A)
Number of subjects: 90
Study: 23681501

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.1 mmol/kg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.3 mmol/kg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Gadobutrol 0.03 mmol/kg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Gadobutrol (all doses)
Number of subjects: 229
Study: 22595446

Group type: EXPERIMENTAL
Intervention: Self-expandable metal stent (SEMS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Plastic stent (PS)
Number of subjects: 108
Study: 20133200

Group type: EXPERIMENTAL
Intervention: rFSH only with GnRH antagonist
Number of subjects: 750

Group type: COMPARATOR
Intervention: P25 subset on stimulation days 1, 5, or 8
Number of subjects: 750
Study: 18226768

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus cardiac resynchronization therapy (CRT)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Optimal medical therapy (OPT)
Number of subjects: 405
Study: 16427528

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine IV before surgical incision, followed by normal saline infusion and normal saline IV at wound closure (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine IV before surgery, followed by ketamine infusion 600 mug . kg(‐1) . h(‐1) until wound closure (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Normal saline IV before surgery, followed by saline infusion and then 0.5 mg/kg ketamine IV at wound closure (Group 3)
Number of subjects: 45
Study: 12714526

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (auto-SCT)
Number of subjects: 734
Study: 11250629

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 108
Study: 9054083

Group type: EXPERIMENTAL
Intervention: Klean‐Prep
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional preparation
Number of subjects: 104
Study: 8307847

Group type: EXPERIMENTAL
Intervention: Propranolol (0.2 mg/kg iv)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg iv)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol or Atropine
Number of subjects: 19
Study: 3554131

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 55) received a three-part individualized course in child safety.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (n = 54) received routine safety education.
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 55) for hazard score assessment.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (n = 54) for hazard score assessment.
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups reported accidents.
Number of subjects: 171
Study: 31100535

Group type: EXPERIMENTAL
Intervention: iGlebe (internet-based cognitive behavior therapy) for 5 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Basic speech-restructuring training (control group)
Number of subjects: 32
Study: 27524365

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 727

Group type: COMPARATOR
Intervention: Control (Citalopram)
Number of subjects: 727
Study: 24907137

Group type: EXPERIMENTAL
Intervention: Pediatric aquatic therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 22887778

Group type: EXPERIMENTAL
Intervention: Combination of 35% comfrey root extract plus 1.2% methyl nicotinate
Number of subjects: 379

Group type: COMPARATOR
Intervention: Methyl nicotinate
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 20102347

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg) injection
Number of subjects: 10
Study: 19248200

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg once daily for 8 weeks)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg once daily for 8 weeks)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Pantoprazole (40 mg once daily for 8 weeks)
Number of subjects: 274
Study: 17602058

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination regimens including thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib, thalidomide, lenalidomide, and other novel agents
Number of subjects: 0
Study: 14767299

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 4 years
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040